1Harries M, Gore M. Part Ⅱ: chemotherapy for epithelial ovarian cancer treatment of recurrent disease[ J ]. Lancet Oncol,2002,3(9) :537 -545. 被引量：1
2Gadducci A, Conte P, Cianci C, et al. Treatment options in patients with recurrent ovarian cancer[ J]. Anticancer Res, 2001,21 ( 5 ) : 3 557 -3 564. 被引量：1
3Dizon DS, Dupont J, Anderson S, et al. Treatment of recurrent ovarian cancer:a retrospective analysis of women treated with single-agent carboplatin originally treated with carboplatin and paclitaxel. The Memorial Sloan-Kettering Cancer center experience[ J]. Gynecol Oncol ,2003,91 ( 3 ) :584 - 590. 被引量：1
4Muggla FM,Hainsworth JD,Jeffers S,et ah Phase Ⅱ study of liposoreal doxorubicin in refractory ovarian cancer, anti-tumor activity and toxicity modification by liposomal encapsulation [ J ]. J Clin Oncol, 1997,15(3) :987 -993. 被引量：1
5Gordon AN ,Fleagle JT,Guthrie D,et al. Recurrent epithelial ovarian carcinoma : a randomized phase Ⅲ study of pegylated liposomal doxorubicin versus topotecan [ J ]. J Clin Oncol, 2001, 19 ( 14 ) : 3 312- 3 322. 被引量：1
6Hoskins PJ, Swenerton KD. Oral etoposide is active against platinumresistant epithelial ovarian cancer[ J ]. J Clin Oncol, 1994, 12 ( 1 ) : 60- 63. 被引量：1
7Rose PG, Blessing JA, Mayer AR, et al. Prolonged oral etoposide as second-line therapy for platinum-resistant and platinum-sensitive ovarian carcinoma: a GOG study [ J]. J Clin oncol, 1998,16 (2): 405 -410. 被引量：1
8Berman ML. Future directions in the surgical management of ovarian cancer[ J ]. Gynecol Oncol,2003,90 (2pt2) :33 - 39. 被引量：1
9Eisenkop SM, Friedman RL, Spirtos NM. The role of secondary cytoreductive surgery in the treatment of patients with recurrent epithelial ovarian carcinoma[ J]. Cancer,2000,88 ( 1 ) :144 - 153. 被引量：1
10Benedet JL, Hacker NF, Ngan Hys. FIGO staging classification and clinical practice guideline in the management of gynecologic cancer [ M ], 2nd ed. New York : Elsevier,2004:63 - 65. 被引量：1
同被引文献11
1Dite F,Baiocchi G.Value of lymph node assessment in ovarian cancer:status of the art at the end of the second millennium[J].Int J gynecol cancer,2000,10(6):435-442. 被引量：1
2Eisenkops SM,Spirtos NM.The clinical significancer of occult macroscopically positive retroperitoneal nodes in patients with epithlial ovarian cancer[J].Gynecol Oncol,2001,82:143-149. 被引量：1
3Alettig D,Dowdy SC,Gostout BS,et al.Aggressive surgical effect and improved survival in advanced-stage ovarian cancer[J].Obstet Gynecol,2006,107:77-85. 被引量：1
4Aletti GD,Cliby WA.Importance of surgical aggressiveness in advanced ovarian cancer[J].J Clin Oncol,2006,24(15):2397-2397. 被引量：1
6DITE F, BAIOCCHI G. Value of lymphnode assessment in ovarian cancer: Statusof the art at the end of the secondmiUennium[J ]. Int J gynecol Cancer, 2000,10 (6) : 435 - 442. 被引量：1
7EISENKOP S M,SPIRTOS N M. The clinical signifi cance of occult rnaeroscopicallypositive retroperitoneal nodes in patients with epithelial ovarian caneer[J ]. Gynecol Oncol,2001,82:143- 149. 被引量：1
8ALETTIG D, DOWDY S C, GOSTOUT B S, etal. Aggressive surgical effort and improvedsurvival in advancedstage ovariancaner[J ]. Obstet Gynecol,2006,107: 77 - 85. 被引量：1
9ALETTI G D,CLIBY W A. Importance of Surgical Aggressiveness in Advanced Ovaria Cancer[ J ]. J Clin Oncol, 2006,24 (15) : 2397 - 2397. 被引量：1
